Bionome Holdings Limited Secures £442.7k in Latest Funding Round, Valued at £20.9m

Bionome Holdings Limited, a London-based company engaged in biotechnology research and experimental development alongside environmental consulting activities, has successfully secured £442.7k in its latest funding round. This recent capital injection, filed on 2026-04-20 with an allotment date of 2026-04-13, places the company's post-money valuation at an estimated £20.9m.

Founded on 2020-03-03, Bionome Holdings Limited operates at the intersection of scientific innovation and environmental stewardship. The company's core activities involve conducting research and experimental development in biotechnology, indicating a focus on advancing scientific understanding and developing novel solutions within this complex field. Concurrently, its provision of environmental consulting activities suggests a commitment to addressing ecological challenges and assisting other entities in navigating environmental regulations and achieving sustainability goals. Specific financial metrics such as revenue, employee count, or profit/loss figures for the company were not disclosed in the available data.

This latest funding round saw Bionome Holdings Limited raise £442.7k, contributing to its current valuation of £20.9m. This round continues a pattern of consistent capital acquisition for the company, demonstrating a steady growth trajectory in its valuation over recent years.

A review of Bionome Holdings Limited's previous funding rounds illustrates this progression: * On 2025-02-28, the company raised £326.9k at a valuation of £20.2m. * Prior to that, on 2024-12-19, it secured £724.8k with a valuation of £19.8m. * A more substantial round on 2023-07-05 brought in £1.2m, pushing its valuation to £12.5m. * Earlier rounds include £30k on 2022-09-05 at a £1.5m valuation, £65k on 2022-08-22 also at a £1.5m valuation, and £55k on 2022-05-09 at a £1.4m valuation.

The consistent increase in valuation, from £1.4m in May 2022 to £20.9m in April 2026, highlights significant investor confidence in Bionome Holdings Limited's potential and its strategic direction across its dual focus areas.

The funding landscape for companies operating in both biotechnology and environmental consulting in the UK presents a mixed but ultimately promising picture.

For the biotechnology sector, 2025 proved to be a challenging financing environment, with the UK biotech sector securing £1.9 billion in equity financing, marking a 49% decrease compared to 2024. Venture capital investment specifically totalled £1.8 billion, representing a 13.2% year-on-year decrease. Deal volume also saw a significant decline, falling by 47.7% from 111 deals in 2024 to 58 deals in 2025. Much of the funding was concentrated in a small number of large rounds, with mid-sized scale-up financings experiencing constraints. Despite these headwinds, the UK maintained its position as Europe's leading national biotech market, accounting for 30% of all European venture financing in 2025. A positive sign emerged in Q4 2025, which recorded the highest quarterly deal count of the year, suggesting a potential improvement in investor sentiment heading into 2026. The pharmaceutical and biotechnology sectors are also noted as leading contributors to the UK's private-sector R&D investment. The UK government has ambitious targets, aiming for the UK to be the "leading Life Sciences economy in Europe by 2030" and among the top three globally by 2035.

In parallel, the environmental consulting and broader climate tech sectors in the UK have demonstrated robust growth. The environmental consultants' revenue is projected to climb at a compound annual rate of 2.7% to £2.7 billion over the five years through 2025-26. This growth is largely driven by the UK government's commitment to achieving net-zero carbon emissions by 2050, which fuels increased demand for environmental consultancies as businesses seek energy-efficient solutions and compliance with environmental standards. The UK's climate tech and sustainability sector experienced a strong year in 2025, with over £400 million raised. Furthermore, the UK CleanTech sector secured an impressive £2.1 billion in climate-focused funding during the first half of 2025, marking a 34% increase from the previous year. This surge is significantly attributed to the growing pressure on institutional investors to meet Environmental, Social, and Governance (ESG) mandates. The integration of AI within climate tech is also expected to accelerate the sector's development. Government initiatives, such as the National Wealth Fund (NWF) and Great British Energy (GBE), are also playing a crucial role in de-risking and complementing private investment in clean energy.

Bionome Holdings Limited's ability to consistently raise capital and increase its valuation, particularly in a period where overall biotech venture funding saw a decline in deal volume, underscores its resilience and the perceived value of its dual focus. By combining biotechnology research with environmental consulting, the company is positioned to capitalise on both the ongoing need for scientific innovation in life sciences and the accelerating demand for solutions to environmental challenges, supported by strong policy drivers and increasing ESG investment in the UK.